KR960703594A - Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments - Google Patents

Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments Download PDF

Info

Publication number
KR960703594A
KR960703594A KR1019960700944A KR19960700944A KR960703594A KR 960703594 A KR960703594 A KR 960703594A KR 1019960700944 A KR1019960700944 A KR 1019960700944A KR 19960700944 A KR19960700944 A KR 19960700944A KR 960703594 A KR960703594 A KR 960703594A
Authority
KR
South Korea
Prior art keywords
compound
formula
carbon atoms
atherosclerosis
general formula
Prior art date
Application number
KR1019960700944A
Other languages
Korean (ko)
Inventor
지그프리트 자이스
디이터 노이저
요한스-피터 스타쉬
지그프리트 골드만
Original Assignee
클라우스 로이터, 귄터 슈마허
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클라우스 로이터, 귄터 슈마허, 바이엘 악티엔게젤샤프트 filed Critical 클라우스 로이터, 귄터 슈마허
Publication of KR960703594A publication Critical patent/KR960703594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 그 일부가 공지되어 있는 하기 일반식 (Ⅰ)의 N-알킬화 1,4-디히드로피리딘디카르복실산 에스테르의 아테롬성 동맥경화증 치료제로서의 용도, 특히 혈관형성술 및 혈관 수술에 따른 재협착증을 예방하기 위한 용도에 관한 것이다.The present invention relates to the use of N-alkylated 1,4-dihydropyridinedicarboxylic acid esters of the following general formula (I), in which a part thereof is known, as a therapeutic agent for atherosclerosis, in particular restenosis following angioplasty and vascular surgery. To prevent use.

상기 식에서, R1내지 R6는 본 명세서에서 정의한 바와 동일하다.Wherein R 1 to R 6 are the same as defined herein.

Description

약제로서의 N-알킬화 1,4-디히드로피리딘디카르복실산 에스테르의 용도 (Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments)Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (7)

아테롬성 동맥경화증을 제어하기 위한 하기 일반식 (Ⅰ)의 N-알킬화 1,4-디히드로피리딘디카르복실산 에스테르의 용도.Use of an N-alkylated 1,4-dihydropyridinedicarboxylic acid ester of the general formula (I) below for controlling atherosclerosis. 상기 식에서, R1은 수소, 니트로, 시아노, 트리플루오로메틸, 트리플루오로메톡시, 할로겐 또는 메틸이고, R2는 수소, 할로겐, 니트로, 히드록실, 트리플루오로메틸 또는 메틸이고, R3는 수소 또는 시아노이거나, 또는 R2및 R3는 함께 융합된 벤조-환을 형성하고, R4및 R5는 동일하거나 또는 상이한 것으로서 탄소수 4 이하의 알콕시에 의해 임의 치환되는 탄소수 8 이하의 직쇄 또는 분지쇄 알킬을 나타내며, R6는 탄소수 6 이하의 직쇄 또는 분지쇄 알킬 또는 탄소수 3 내지 7의 시클로알킬을 나타낸다.Wherein R 1 is hydrogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, halogen or methyl, R 2 is hydrogen, halogen, nitro, hydroxyl, trifluoromethyl or methyl, R 3 Is hydrogen or cyano, or R 2 and R 3 together form a fused benzo-ring, and R 4 and R 5 are the same or different and are straight chains having up to 8 carbon atoms optionally substituted by alkoxy having up to 4 carbon atoms; Or branched alkyl, R 6 represents linear or branched alkyl having 6 or less carbon atoms or cycloalkyl having 3 to 7 carbon atoms. 제1항에 있어서, 재협착증을 치료 및 예방하기 위한 일반식(Ⅰ)의 화합물의 용도.Use of a compound of formula (I) according to claim 1 for treating and preventing restenosis. 제1항에 있어서, 혈관벽 손상에 따른 평활근 세포에서의 내막증식을 억제하기 위한 일반식 (Ⅰ)의 화합물의 용도.Use of a compound of formula (I) according to claim 1 for inhibiting endothelium proliferation in smooth muscle cells following vascular wall injury. 제1항에 있어서, 아테롬성 동맥경화증의 제어용 약제를 제조하기 위한 일반식(Ⅰ)의 화합물의 용도.Use of a compound of formula (I) according to claim 1 for the preparation of a medicament for the control of atherosclerosis. 제1항에 있어서, 혈관벽 손상에 따른 재협착증의 예방 및 제어용 약제를 제조하기 위한 일반식(Ⅰ)의 화합물의 용도.Use of a compound of formula (I) according to claim 1 for the preparation of a medicament for the prevention and control of restenosis caused by vascular wall injury. 제1항에 따른 일반식(Ⅰ)의 화합물 중 1종 이상의 화합물을 함유하는 아테롬성 동맥경화증 치료제.An agent for treating atherosclerosis containing at least one compound of the compound of general formula (I) according to claim 1. 제1항에 따른 일반식(Ⅰ)의 화합물 중 1종 이상의 화합물을 임의로는 통상의 보조 물질 및 부형제를 사용하여 투여하기에 적합한 형태로 전환시킴을 특징으로 하여 아테롬성 동맥경화증 치료제를 제조하는 방법.A method for preparing an agent for treating atherosclerosis, characterized by converting at least one compound of the general formula (I) according to claim 1 into a form suitable for administration, optionally using conventional auxiliary substances and excipients. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960700944A 1993-08-27 1994-08-16 Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments KR960703594A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4328884.7 1993-08-27
DE4328884A DE4328884A1 (en) 1993-08-27 1993-08-27 Use of N-alkylated 1,4-dihydropyridinecarboxylic acid esters as medicaments
PCT/EP1994/002723 WO1995005823A1 (en) 1993-08-27 1994-08-16 Use of n-alkylated 1,4-dihydropyridine dicarboxylic acid esters as medicaments

Publications (1)

Publication Number Publication Date
KR960703594A true KR960703594A (en) 1996-08-31

Family

ID=6496196

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700944A KR960703594A (en) 1993-08-27 1994-08-16 Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments

Country Status (13)

Country Link
EP (1) EP0714301A1 (en)
JP (1) JPH09501923A (en)
KR (1) KR960703594A (en)
CN (1) CN1129906A (en)
AU (1) AU7613594A (en)
BG (1) BG100367A (en)
CA (1) CA2170285A1 (en)
CZ (1) CZ43896A3 (en)
DE (1) DE4328884A1 (en)
HU (1) HUT75302A (en)
NO (1) NO960777L (en)
PL (1) PL313116A1 (en)
WO (1) WO1995005823A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741694C2 (en) * 1997-09-18 2002-10-31 Schering Ag Use of complexes whose ligand is a bis-amine oxime derivative or an N¶2¶S¶2¶ derivative and whose central atom is a radionuclide
ES2271365T3 (en) 2001-12-20 2007-04-16 Bayer Healthcare Ag DERIVATIVES OF 1,4-DIHIDRO-1,4-DIFENYLPIRIDINE.
US10258498B2 (en) * 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3222367A1 (en) * 1982-06-15 1983-12-15 Bayer Ag, 5090 Leverkusen Use of 1,4-dihydropyridines in antiarteriosclerotics and preparation thereof
EP0169009A3 (en) * 1984-07-17 1988-08-31 FISONS plc Novel dihydropyridine derivatives and their production, formulation and use as pharmaceuticals
DE4011695A1 (en) * 1990-04-11 1991-10-17 Bayer Ag USE OF N-ALKYLATED 1,4-DIHYDROPYRIDE INDICARBOXIC ACID ESTERS AS DRUGS, NEW COMPOUNDS AND METHOD FOR THEIR PREPARATION

Also Published As

Publication number Publication date
AU7613594A (en) 1995-03-21
JPH09501923A (en) 1997-02-25
HUT75302A (en) 1997-05-28
WO1995005823A1 (en) 1995-03-02
HU9600472D0 (en) 1996-04-29
CA2170285A1 (en) 1995-03-02
NO960777D0 (en) 1996-02-26
CZ43896A3 (en) 1996-05-15
DE4328884A1 (en) 1995-03-02
BG100367A (en) 1996-07-31
CN1129906A (en) 1996-08-28
EP0714301A1 (en) 1996-06-05
PL313116A1 (en) 1996-06-10
NO960777L (en) 1996-04-10

Similar Documents

Publication Publication Date Title
KR960703585A (en) Method to inhibit restenosis
RU99114020A (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES
AU7476894A (en) Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
RU2004126705A (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES
DE69032414D1 (en) Diphenylmethane derivatives, processes for their preparation and pharmaceutical compositions containing them
MX9207224A (en) APOLIPOPROTEIN.
EP0602586A3 (en)
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
KR930700450A (en) Antimicrobial Quinolone Thiourea
WO1999012532A3 (en) Piperidine derivatives against malaria
JPS57185275A (en) Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
KR960013370A (en) Triglyceride Excess Prevention Composition
KR950700255A (en) Pyridine Carboximideamide Compounds and Their Uses (PYRIDINECARBOXIMIDAMIDE COMPOUNDS AND THE USE THEREOF)
KR950704314A (en) 1,8-naphthyridin-2-one derivatives and methods of use thereof (1,8-NAPHTHYRIDIN-2-ONE DERIVATIVE AND USE THEREOF)
KR950016727A (en) How to increase thrombomodulin expression
NO20014119L (en) Medication containing a sulfopyranosylacylglycerol derivative
KR950703941A (en) Nitrogen monoxide synthase inhibitor (NITROGEN MONOXIDE SYNTHESIS INHIBITOR)
KR960703594A (en) Use Of N-Alkylated 1,4-Dihydropyridine Dicarboxylic Acid Esters as Medicaments
KR940021064A (en) How to use pregne derivatives
RU98100111A (en) ACTIVE OSTEOGENESIS PHARMACEUTICAL COMPOSITION
KR960703593A (en) Inhibition of Smooth Muscle Cell Migration by (R) -Amlodipine
ATE149165T1 (en) BIZYCLIC DERIVATIVES CONTAINING NITROGEN, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
KR870005641A (en) Hypertension Treatment Composition
KR940701251A (en) Cholesterol-lowering Tocopherol Homolog
BE881834A (en) DRUGS AND PHARMACEUTICAL PREPARATIONS WITH CYTOSTATIC ACTIVITY

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid